Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
Anticancer Res
; 37(6): 3169-3174, 2017 06.
Article
em En
| MEDLINE
| ID: mdl-28551660
ABSTRACT
BACKGROUND/AIM:
Reportedly, hypertension tends to be associated with response to bevacizumab therapy, because bevacizumab suppresses vascular nitric oxide production. In this study we examined the predictive value of nitric oxide in bevacizumab-treated non-small cell lung cancer (NSCLC) patients. PATIENTS ANDMETHODS:
Fifteen patients with advanced or recurrent NSCLC treated with bevacizumab-based regimens were evaluated retrospectively. Serum NOx (NO2-/NO3-) was assayed by the Griess method.RESULTS:
Serum nitric oxide levels were decreased after two courses of bevacizumab treatment in our responder group (p=0.02). According to the change in nitric oxide levels after the second course of treatment, median progression-free survival was 11.0 months in the group with decreased serum nitric oxide and 7.6 months in the group with increased serum nitric oxide (p=0.08).CONCLUSION:
Serum nitric oxide levels could be a predictive biomarker for response to bevacizumab in NSCLC patients.Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Biomarcadores Farmacológicos
/
Bevacizumab
/
Neoplasias Pulmonares
/
Óxido Nítrico
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Japão